NMTC stock forecast is benefiting from a sector rotation into value-oriented tech plays. Analysts project EPS growth of 5% for FY2024, supported by cost management and niche market expansion. Watch MACD crossovers for confirmation of sustained upward momentum. NeuroOne Medical Technologies Corporation NMTC recently received FDA 510(k) clearance for its OneRF Trigeminal Nerve Ablation System, a minimally invasive solution for treating severe facial pain. The system delivers targeted radiofrequency energy to ablate trigeminal nerve fibers, offering an alternative to traditional medications or invasive surgical procedures. NMTC now targets a limited commercial launch in the fourth quarter of 2025. $NMTC insiders have traded $NMTC stock on the open market 5 times in the past 6 months. Of those trades, 2 have been purchases and 3 have been sales. Short-term NMTC stock forecast momentum is supported by RSI readings below overbought levels, leaving room for further gains without immediate correction pressure. Options data also shows rising call interest for near-term expirations.
